HER2 + breast cancers evade anti-HER2 therapy via a switch in driver pathway

Inhibition of HER2 in HER2-amplified breast cancer has been remarkably successful clinically, as demonstrated by the efficacy of HER-kinase inhibitors and HER2-antibody treatments. Whilst resistance to HER2 inhibition is common in the metastatic setting, the specific programs downstream of HER2 driv...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Alison E., Ferraro, Emanuela, Safonov, Anton, Morales, Cristina Bernado, Lahuerta, Enrique J. Arenas, Li, Qing, Kulick, Amanda, Ross, Dara, Solit, David B., de Stanchina, Elisa, Reis-Filho, Jorge, Rosen, Neal, Arribas, Joaquín, Razavi, Pedram, Chandarlapaty, Sarat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602441/
https://www.ncbi.nlm.nih.gov/pubmed/34795269
http://dx.doi.org/10.1038/s41467-021-27093-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602441/
https://www.ncbi.nlm.nih.gov/pubmed/34795269
http://dx.doi.org/10.1038/s41467-021-27093-y

Ejemplares similares